Structural and Hormonal Changes in Reproductive-Age Women Post-COVID-19: A Cross-Sectional Ultrasound and Biochemical Study.

Publication date: Jun 17, 2025

Background/Objectives: The long-term impact of COVID-19 on female reproductive health remains poorly understood. This study aimed to assess structural and endocrine alterations in women of reproductive age who had recovered from SARS-CoV-2 infection compared to uninfected controls. Materials and Methods: A total of 150 women aged 18-45 years were enrolled in a comparative study: 75 with a confirmed history of COVID-19 and 75 without one. All participants underwent ultrasound examinations of their pelvic organs and mammary glands, along with laboratory assessment of reproductive hormones and inflammatory markers. Results: Structural abnormalities in the pelvic organs were observed in 53. 5% of the post-COVID-19 group versus 12. 0% of the control group (p < 0. 001), with oophoritis showing a statistically significant association (OR = 11. 38; 95% CI: 1. 42-91. 36; p = 0. 009). Non-significant but elevated frequencies were also found for uterine fibroids and breast cysts. Biochemically, post-COVID-19 participants demonstrated higher serum ferritin, estradiol, and fibrinogen levels, along with lower TSH and AMH levels, suggesting potential endocrine disruption and persistent inflammation. Conclusions: Women with a history of COVID-19 may be at increased risk of developing structural and hormonal abnormalities, highlighting the importance of post-infection gynecological and endocrine monitoring. Further longitudinal studies are required to elucidate the long-term effects and underlying mechanisms of these alterations.

Open Access PDF

Concepts Keywords
Basel AMH
Gynecological COVID-19
Poorly endocrine disruption
Ultrasound estradiol
Women ovarian function
pelvic ultrasound
post-COVID-19
reproductive health
women’s health

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease IDO history
disease MESH abnormalities
disease MESH oophoritis
disease MESH uterine fibroids
disease MESH breast cysts
drug DRUGBANK Estradiol
drug DRUGBANK Fibrinogen Human
disease MESH inflammation
disease MESH infection
disease MESH Long Covid
drug DRUGBANK Naproxen
drug DRUGBANK Isoxaflutole
disease MESH dysmenorrhea
disease MESH fibrocystic mastopathy
disease MESH follicular cysts
disease MESH endometrial hyperplasia
drug DRUGBANK Follitropin
disease MESH syndrome
disease MESH complications
disease MESH Infectious Diseases
drug DRUGBANK Methionine
disease MESH chronic diseases
disease IDO process
drug DRUGBANK Methylergometrine
disease MESH ovarian cysts
disease MESH endometriosis
disease MESH Tumor
disease MESH adnexal torsion
disease MESH cysts
disease IDO blood
drug DRUGBANK Etoperidone
disease MESH menstrual irregularities
disease IDO facility
drug DRUGBANK Progesterone
disease IDO assay
disease MESH gynecologic diseases
disease MESH marital status
disease MESH varicose veins
disease MESH general health
disease MESH hypercoagulability
drug DRUGBANK Trestolone
drug DRUGBANK Aspartame
disease MESH privacy
disease MESH emergencies
disease MESH Atherosclerosis
disease MESH Cytokine storm
disease MESH live births
disease MESH pregnancy outcomes
disease IDO susceptibility
disease MESH ectopic pregnancy
pathway REACTOME Reproduction
disease MESH bleeding
disease MESH cardiovascular disease
disease MESH diabetes mellitus
disease MESH stroke
disease MESH Urinary Tract Infections
disease MESH Infertility

Original Article

(Visited 10 times, 1 visits today)